Canbex Therapeutics Limited

Founded in 2005, Canbex Therapeutics is a developer of active compounds in the field of spasticity and pain. The company develops peripherally-acting cannabinoid antagonists for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.

Canbex Therapeutics is a joint investment collaboration with BBSF (Bloomsbury Bio-Seed Fund) and the recipient of a Wellcome translation award. The company portfolio includes two different series of compounds that have been extensively characterised in MS models. The company is a licensing vehicle for this breakthrough technology and research work is being carried on this project at UCL, Queen Mary's and Cambridge Universities. The company is managed and supported by UCL Business' management team.


Canbex Therapeutics Ltd.
The Network Building
97 Tottenham Court Road
W1T 4TP

T. 020 7679 9000
E. enquiries@canbex.co.uk

Company number: 05073720